Table 2 Clinico-pathological parameters, Miller-Payne grade and follow up information of 12 ASCO/CAP group 2 patients who underwent neoadjuvant therapy prior to surgery
Case | Age | MP grade | Histological subtype | Histological grade | Diameter(cm) | ALN | HER2 IHC | HER2 status according to 2018 ASCO/CAP | Immunohistochemical surrogate subtype | Anti-HER2 therapy | Disease progresions | Follow up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 39 | NA | NA | NA | NA | NA | 1 | non-amplification | TNBC | Y | Y, metastasis before anti-HER2 therapy | survive,39 months |
2 | 43 | 3 | ICONST | 2 | 2 | 0/15 | 1 | non-amplification | Luminal A | Y | N | survive,38 months |
3 | 52 | NA | NA | NA | NA | NA | 1 | non-amplification | Luminal B | N | N | survive,39 months |
4 | 49 | 3 | invaisive carcinoma with neuroendocrine differentiation | 2 | 1.5 | 0/8 | 2 | non-amplification | Luminal A | N | N | survive,44 months |
5 | 57 | NA | NA | NA | NA | NA | 2 | non-amplification | Luminal B | N | Y,16 months | die,16 months |
6 | 41 | 5 | / | / | / | 0/19 | 1 | non-amplification | TNBC | Y | N | survive,29 months |
7 | 39 | 3 | ICONST | 2 | 1.7 | 1/18 | 2 | non-amplification | Luminal B | Y | N | survive,24 months |
8 | 63 | 3 | ICONST | 2 | 3.6 | 3/14 | 1 | non-amplification | Luminal B | Y | N | survive,24 months |
9 | 52 | NA | NA | NA | NA | NA | 2 | non-amplification | Luminal B | Y | Y, metastasis before anti-HER2 therapy | die,20 months |
10 | 50 | 4 | ICONST | / | / | 0/13 | 2 | non-amplification | TNBC | Y | N | survive,20 months |
11 | 36 | 5 | / | / | / | 0/10 | 1 | non-amplification | TNBC | N | N | survive,41 months |
12 | 68 | NA | NA | NA | NA | NA | 2 | non-amplification | TNBC | N | Y,16 months | die,16 months |